Archives
- 2026-03
- 2026-02
- 2026-01
- 2025-12
- 2025-11
- 2025-10
- 2025-09
- 2025-03
- 2025-02
- 2025-01
- 2024-12
- 2024-11
- 2024-10
- 2024-09
- 2024-08
- 2024-07
- 2024-06
- 2024-05
- 2024-04
- 2024-03
- 2024-02
- 2024-01
- 2023-12
- 2023-11
- 2023-10
- 2023-09
- 2023-08
- 2023-07
- 2023-06
- 2023-05
- 2023-04
- 2023-03
- 2023-02
- 2023-01
- 2022-12
- 2022-11
- 2022-10
- 2022-09
- 2022-08
- 2022-07
- 2022-06
- 2022-05
- 2022-04
- 2022-03
- 2022-02
- 2022-01
- 2021-12
- 2021-11
- 2021-10
- 2021-09
- 2021-08
- 2021-07
- 2021-06
- 2021-05
- 2021-04
- 2021-03
- 2021-02
- 2021-01
- 2020-12
- 2020-11
- 2020-10
- 2020-09
- 2020-08
- 2020-07
- 2020-06
- 2020-05
- 2020-04
- 2020-03
- 2020-02
- 2020-01
- 2019-12
- 2019-11
- 2019-10
- 2019-09
- 2019-08
- 2019-07
- 2019-06
- 2019-05
- 2019-04
- 2018-07
-
To date no studies have demonstrated any effect of
2021-12-21

To date, no studies have demonstrated any effect of obesity or inflammation on GPR109A expression in adipose tissue. Our findings demonstrate that HFD-induced obesity decreases adipose tissue GPR109A gene expression. Contradictory to our findings in adipose tissue in vivo, Digby et al. report that e
-
To apply the recently developed GPR ligands
2021-12-21

To apply the recently developed GPR35 ligands to CNS disorders, it is necessary to understand whether GPR35 is expressed by any identified cell types in the pkm2 and whether activation or blockade of this receptor has any consequence on the activity of the neuronal circuitry. To this end, the prese
-
(S)-(+)-Dimethindene maleate sale br GPR a G protein coupled
2021-12-21

GPR35, a G protein-coupled receptor (GPCR), was discovered and classified as an orphan GPCR in 1998 and deorphanized in 2006 by the discovery of kynurenic (S)-(+)-Dimethindene maleate sale as the endogenous agonist. Since its discovery, limited references on the GPR35 receptor have appeared, due
-
In summary through medicinal chemistry
2021-12-21

In summary, through medicinal chemistry design and computer-assisted conformational modeling, the initial lead was evolved into a series of dihydrobenzofuran derivatives, , as potent GPR119 agonists. Optimization of general structure at various regions of the molecule, including the substituent on
-
br Acknowledgments This publication was supported by NORAD N
2021-12-21

Acknowledgments This publication was supported by NORAD (Norwegian Agency for Development Cooperation) under the NORHED-Program, agreement no. ETH-13/0024. MCM works at the MRC Integrative Epidemiology Unit which receives infrastructure funding from the UK Medical Research Council (MRC) (MC_UU_12
-
nitric oxide synthase inhibitor br Materials and methods br
2021-12-21

Materials and methods Results Discussion Since 1990s, solving structures for most DNA glycosylases by X-ray crystallography significantly advanced mechanistic understanding of the catalytic activity and substrate specificity of this important class of DNA repair enzymes. However, static str
-
While the S site has been implicated in binding
2021-12-21

While the S2 site has been implicated in binding, it lactone is unclear whether the S2 site plays a role in the substrate transport process. Crystal structures have revealed that different drugs and detergents can bind to the S2 site of SERT [8] and LeuT [[13], [14], [15]]. However, there are no cr
-
In summary this study shows that
2021-12-21

In summary, this study shows that compound 4d has strong clinical potential as an efficient GLP-1/GCGR agonist exhibits weight-lowering, lipid-regulation and diabetes-protective effects and plays an important role in the prevention and therapy of diet induced obesity and dyslipidemia. The present st
-
To obviate the mitogenic FGF activity
2021-12-21

To obviate the mitogenic FGF19 activity, several engineered FGF19 variants have been generated aiming to maintain the metabolic activity excluding the protumorigenic ones. One variant, M70, that differs from wild-type FGF19 by 5-amino acids deletion at the N-terminus and the substitution of 3-amino
-
We have isolated various bioactive peptides acting by bindin
2021-12-21

We have isolated various bioactive ProteOrange acting by binding to the receptors of endogenous bioactive peptides such as opioid, bradykinin, neurotensin, and complements C3a and C5a etc. [24]. Rubimetide is the first example of an agonist peptide of the FPR2 of exogenous origin. Anxiolytic-like
-
In the phylum Cnidaria which
2021-12-21

In the phylum Cnidaria, which separated from the main line of Metazoa early during evolution, FGFR signaling is essential during development and morphogenesis. Two FGFRs and two FGFs antagonistically control formation of the apical organ in the anthozoan Nematostella and target the MAPK pathway (Ren
-
BDNF is intricately implicated in energy homeostasis
2021-12-21

BDNF is intricately implicated in energy homeostasis (Hamdouchi et al., 2016; Schwartz and Mobbs, 2012), regulation of mood (Sartorius et al., 2015) and adult neurogenesis (Taliaz et al., 2010; Waterhouse et al., 2012), our primary focus was to evaluate the effects of GPR40 stimulation on BDNF expre
-
The suboptimal trypsin selectivity profile of DPC p http
2021-12-21

The suboptimal trypsin selectivity profile of DPC423 prompted us to investigate additional P moieties for potency and selectivity. Glycinamide P () showed low nanomolar binding affinity against fXa which suggested that this P moiety sits deeper into the S pocket of fXa. To further elaborate on this
-
While more detailed molecular studies on the mechanistic
2021-12-20

While more-detailed molecular studies on the mechanistic basis for heightened H3 receptor function in PAE rats are underway, we have also been exploring whether PAE alters other markers of histaminergic neurotransmission in affected brain regions. One question is whether PAE affected the number of h
-
br Modulators of the GUCY C cGMP PDEs signaling
2021-12-20

Modulators of the GUCY2C/cGMP/PDEs signaling pathways for CRC prevention and therapy (pre-clinical and clinical development) Several modulators of the GUCY2C/cGMP/PDEs signaling pathways, including GUCY2C agonists and PDEs inhibitors, have been developed and explored as chemopreventive agents for
16057 records 554/1071 page Previous Next First page 上5页 551552553554555 下5页 Last page